74f8dc07-b42e-46a4-954f-a36d7bf664d3
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.360
- G2M_CHECKPOINT+0.260
- E2F_TARGETS+0.250
- OXIDATIVE_PHOSPHORYLATION+0.220
- MYC_TARGETS_V2+0.210
- PROTEIN_SECRETION+0.160
- DNA_REPAIR+0.130
- MITOTIC_SPINDLE+0.120
- PI3K_AKT_MTOR_SIGNALING+0.110
- GLYCOLYSIS+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- INFLAMMATORY_RESPONSE-0.450
- IL6_JAK_STAT3_SIGNALING-0.440
- APICAL_SURFACE-0.360
- COMPLEMENT-0.350
- MYOGENESIS-0.280
- KRAS_SIGNALING_UP-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR26320084 | — | — | 0.932 |
| 2 | SRR8943005 | — | — | 0.914 |
| 3 | TCGA-22-A5C4-01A-12R-A27Q-07 | — | cohortSQ1 | 0.909 |
| 4 | SRR1797243 | — | cohortSC | 0.907 |
| 5 | SRR13780247 | — | cohortMD1 | 0.892 |
| 6 | SRR8518240 | — | E | 0.888 |
| 7 | TCGA-AN-A04D-01A-21R-A034-07 | — | E | 0.887 |
| 8 | SRR5088887 | — | — | 0.885 |
| 9 | BS_1HQ76V6D | Embryonal tumors | — | 0.883 |
| 10 | BS_JFB984RG | medulloblastoma | — | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |
| HYPOXIA | 0.010 | Idelalisib | — uncovered |